

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Kempf, et al.

Serial No.: 10/802,829

Filed: August 3, 2004

Title: A METHOD FOR TREATING A
DISEASE, DISORDER OR ADVERSE
EFFECT CAUSED BY AN ELEVATED
SERUM CONCENTRATION OF AN
UGT1A1 SUBSTRATE

Group Art No.: 1614

Examiner: Raymond J. Henley III

Docket No.: 7050USO2

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450



**Certificate of Mailing under 37 CFR
§1.8(a)**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Kim Annel 10/24/04
Kim Annel Date

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

The following information is submitted, pursuant to 37 CFR §§1.97-1.98 in accordance with Applicant's duty of disclosure under 37 CFR §1.56. This submission is not intended to constitute an admission that any patent, publication or other information cited herein is "prior art" as to the invention claimed. In accordance with 37 CFR §§1.97(g)-(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that other material information as defined by 37 CFR §1.56(a) exists.

Applicants submit herewith Form PTO-1449 listing the references known to them. Applicants respectfully request that the Examiner (1) initial each reference listed on the enclosed Form PTO-1449 indicating that the Examiner has considered and made those references of record in this application and (2) return a copy of the initialed Form PTO-1449 to Applicants. Pursuant to 37 CFR 1.98(2), copies of U.S. patents and U.S. patent application publications are not provided. However, copies of all non-U.S. patent and U.S. patent application publication references are enclosed.


This Supplemental Information Disclosure Statement is being filed after the mailing date of a first Office Action on the merits under 37 CFR §1.97(c). The Commissioner is hereby authorized to charge the fee of \$180.00 to Deposit Account 01-0025 under §1.17(p).

10/27/2006 SFELEKE1 00000059 010025 10802829

01 FC:1806 180.00 DA

ABBOTT LABORATORIES
Customer Number 23492
Telephone: (847) 935-1133
Facsimile: (847) 938-2623

Respectfully submitted,
Kempf, et al.



Xu Zhang
Lim Rec No. L0116
Attorney for Applicants



DATE: October 24, 2006 SHEET 1_ of 1_

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98 (b))

ATTY. DOCKET NO.

7050USO2

SERIAL NO.

10/802,829

APPLICANT(S)

Kempf et al.

FILING DATE

8/3/04

GROUP

1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

C1	O'Mara E. et al., "Steady state pharmacokinetic interaction study of atazanavir (ATV) with efavirenz (EFV) and ritonavir (RTV) in healthy subjects" Programs and abstracts of the 9 th Conference on Retroviruses and Opportunistic Infections; February 24-28, 2002, Seattle, Washington. Abstract 444.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)